<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745715</url>
  </required_header>
  <id_info>
    <org_study_id>A-ER-109-437</org_study_id>
    <nct_id>NCT04745715</nct_id>
  </id_info>
  <brief_title>Genomic Study in Non-small Cell Lung Cancer Brain Metastasis</brief_title>
  <official_title>Genomic Analysis in Surgically Treated NSCLC Brain Metastasis Based on Neurosurgical Perspectives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators collected the data from the investigators' center between January 2011 and&#xD;
      October 2020. The study included all non-small cell lung cancer patients with surgically&#xD;
      excised brain metastasis. The investigators analysis the correlation of gene mutation and the&#xD;
      disease course.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators collected the data from from the investigators' center between January 2011&#xD;
      and October 2020. The study included all non-small cell lung cancer patients with surgically&#xD;
      excised brain metastasis. The investigators analysis the correlation of gene mutation and the&#xD;
      disease course. The investigators use Kaplan-Meier regression to analyze the overall&#xD;
      survival, and the difference between the groups was calculated using log rank test. Cox&#xD;
      proportional hazards method was used to create the regression model and estimate the hazard&#xD;
      ratios.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2011</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative survival</measure>
    <time_frame>From date of craniectomy until the date of patient deceased or date of last followed medical record, with median follow up around to 20 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>NSCLC Stage IV</condition>
  <condition>Brain Metastases</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>craniectomy</intervention_name>
    <description>craniectomy outcomes and survival</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with non-small cell lung cancer underwent craniectomy, who completed postoperative&#xD;
        whole brain radiotherapy and associated chemo or target therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - patients diagnosed with non-small cell lung cancer who underwent craniectomy and&#xD;
        subsequent whole brain radiotherapy and associated chemo or target therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient who did not receive postoperative adjuvant therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jung Shun Lee, MD. Msc.</last_name>
    <phone>886-6-2353535</phone>
    <phone_ext>5181</phone_ext>
    <email>nslee1218@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cheng Kung University hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Shun Lee, MD. Msc</last_name>
      <phone>886-6-2766676</phone>
      <phone_ext>5181</phone_ext>
      <email>nslee@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 7, 2021</last_update_submitted>
  <last_update_submitted_qc>February 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

